Predictive Cardiac Hypertrophy Biomarkers in Nonclinical Studies

PREDICTIVE CARDIAC HYPERTROPHY BIOMARKERS IN NONCLINICAL STUDIES 

Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA 

---

Matrix metalloproteinases (MMP), tissue inhibitors of metalloproteinase (TMP), and collagen propeptides (PIIINP) are also indicative of remodeling that occurs during cardiac hypertrophy, but are also nonspecific and consistent with more advanced hypertrophy than occurs in short-duration animal studies. A panel consisting of MMP-7, MMP-9, TIMP-1, PIIINP, and NTproBNP has shown promise in predicting the presence of cardiac hypertrophy in humans with hypertension and may prove useful in animal studies however, further research is needed (Zile et al., 2011). Osteoprotegerin (OPG), a member of the TNF receptor superfamily, has shown promise as a biomarker of cardiac hypertrophy however, little is known regarding the utihty of OPG in the context of nonclinical safety studies (Coutinho et al., 2011 Koyama et al., 2014). 

---